Stroke and Hypertension: An Appraisal from Pathophysiology to Clinical Practice

Author(s): Agata Buonacera, Benedetta Stancanelli, Lorenzo Malatino*.

Journal Name: Current Vascular Pharmacology

Volume 17 , Issue 1 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Stroke as a cause of long-term disability is a growing public health burden. Therefore, focusing on prevention is important. The most prominent aim of this strategy is to treat modifiable risk factors, such as arterial hypertension, the leading modifiable contributor to stroke. Thus, efforts to adequately reduce Blood Pressure (BP) among hypertensives are mandatory. In this respect, although safety and benefits of BP control related to long-term outcome have been largely demonstrated, there are open questions that remain to be addressed, such as optimal timing to initiate BP reduction and BP goals to be targeted. Moreover, evidence on antihypertensive treatment during the acute phase of stroke or BP management in specific categories (i.e. patients with carotid stenosis and post-acute stroke) remain controversial.

This review provides a critical update on the current knowledge concerning BP management and stroke pathophysiology in patients who are either at risk for stroke or who experienced stroke.

Keywords: Arterial hypertension, stroke, blood pressure, vascular prevention, pathophysiology, cardiovascular risk.

[1]
GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388(10053): 1459-544.
[2]
Koton S, Schneider AL, Rosamond WD, et al. Stroke incidence and mortality trends in US communities, 1987 to 2011. JAMA 2014; 312(3): 259-68.
[3]
Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990-2010: Findings from the global burden of disease study 2010. Lancet 2014; 383(9913): 245- 54. Erratum in: Lancet 2014; 383(9913): 218.
[4]
Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: A report from the American Heart Association. Circulation 2017; 135(10): e146-e603. Erratum in: Circulation 2017; 135(10): e646.
[5]
Sacco S, Stracci F, Cerone D, Ricci S, Carolei A. Epidemiology of stroke in Italy. Int J Stroke 2011; 6(3): 219-27.
[6]
Yaghi S, Bernstein RA, Passman R, Okin PM, Furie KL. Cryptogenic Stroke: Research and practice. Circ Res 2017; 120(3): 527-40.
[7]
Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: Incidence, recurrence, and long-term survival in ischemic stroke subtypes: A population-based study. Stroke 2001; 32(12): 2735-40.
[8]
Li L, Yiin GS, Geraghty OC, et al. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: A population-based study. Lancet Neurol 2015; 14(9): 903-13.
[9]
Ntaios G, Papavasileiou V, Milionis H, et al. Embolic strokes of undetermined source in the Athens stroke registry: A descriptive analysis. Stroke 2015; 46(1): 176-81.
[10]
Marnane M, Duggan CA, Sheehan OC, et al. Stroke subtype classification to mechanism-specific and undetermined categories by TOAST, A-S-C-O, and causative classification system: Direct comparison in the North Dublin population stroke study. Stroke 2010; 41(8): 1579-86.
[11]
O’Donnell MJ, Xavier D, Liu L, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): A case-control study. Lancet 2010; 376(9735): 112-23.
[12]
Feigin VL, Roth GA, Naghavi M, et al. Global burden of stroke and risk factors in 188 countries, during 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurol 2016; 15(9): 913-24.
[13]
Boehme AK, Esenwa C, Elkind MS. Stroke risk factors, genetics, and prevention. Circ Res 2017; 120(3): 472-95.
[14]
D’Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: Adjustment for antihypertensive medication. The Framingham Study. Stroke 1994; 25(1): 40-3.
[15]
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349): 1903-13. Erratum in: Lancet. 2003; 361(9362): 1060.
[16]
Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: Lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 2014; 383(9932): 1899-911.
[17]
Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: A systematic review. Lancet Neurol 2007; 6(7): 611-9.
[18]
Prabhakaran S, Wright CB, Yoshita M, et al. Prevalence and determinants of subclinical brain infarction: The Northern Manhattan Study. Neurology 2008; 70(6): 425-30.
[19]
Das RR, Seshadri S, Beiser AS, et al. Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study. Stroke 2008; 39(11): 2929-35.
[20]
Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375(9718): 895-905.
[21]
Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 2010; 375(9718): 938-48.
[22]
Garcia JH, Ho KL. Pathology of hypertensive arteriopathy. Neurosurg Clin N Am 1992; 3(3): 497-507.
[23]
Zia E, Hedblad B, Pessah-Rasmussen H, Berglund G, Janzon L, Engström G. Blood pressure in relation to the incidence of cerebral infarction and intracerebral hemorrhage. Hypertensive hemorrhage: debated nomenclature is still relevant. Stroke 2007; 38(10): 2681-5.
[24]
Kazui S, Minematsu K, Yamamoto H, Sawada T, Yamaguchi T. Predisposing factors to enlargement of spontaneous intracerebral hematoma. Stroke 1997; 28(12): 2370-5.
[25]
Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997; 28(1): 1-5.
[26]
Fujii Y, Takeuchi S, Sasaki O, Minakawa T, Tanaka R. Multivariate analysis of predictors of hematoma enlargement in spontaneous intracerebral hemorrhage. Stroke 1998; 29(6): 1160-6.
[27]
Jauch EC, Lindsell CJ, Adeoye O, et al. Lack of evidence for an association between hemodynamic variables and hematoma growth in spontaneous intracerebral hemorrhage. Stroke 2006; 37(8): 2061-5.
[28]
Broderick JP, Diringer MN, Hill MD, et al. Determinants of intracerebral hemorrhage growth: An exploratory analysis. Stroke 2007; 38(3): 1072-5.
[29]
Ohwaki K, Yano E, Nagashima H, Hirata M, Nakagomi T, Tamura A. Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement. Stroke 2004; 35(6): 1364-7.
[30]
Fisher CM. Lacunar strokes and infarcts: A review. Neurology 1982; 32(8): 871-6.
[31]
Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types: Results from an international collaboration. International Stroke Incidence Collaboration. Stroke 1997; 28(3): 491-9.
[32]
Fisher CM. Lacunes: Small, deep cerebral infarcts. Neurology 1965; 15: 774-84.
[33]
Bailey EL, McCulloch J, Sudlow C, Wardlaw JM. Potential animal models of lacunar stroke: A systematic review. Stroke 2009; 40(6): e451-8.
[34]
Sironi L, Guerrini U, Tremoli E, et al. Analysis of pathological events at the onset of brain damage in stroke-prone rats: A proteomics and magnetic resonance imaging approach. J Neurosci Res 2004; 78(1): 115-22.
[35]
Ogata J, Fujishima M, Tamaki K, Nakatomi Y, Ishitsuka T, Omae T. Vascular changes underlying cerebral lesions in stroke-prone spontaneously hypertensive rats. A serial section study. Acta Neuropathol 1981; 54(3): 183-8.
[36]
Kim-Mitsuyama S, Yamamoto E, Tanaka T, et al. Critical role of angiotensin II in excess salt-induced brain oxidative stress of stroke-prone spontaneously hypertensive rats. Stroke 2005; 36(5): 1083-8.
[37]
Volpe M, Iaccarino G, Vecchione C, et al. Association and cosegregation of stroke with impaired endothelium-dependent vasorelaxation in stroke prone, spontaneously hypertensive rats. J Clin Invest 1996; 98(2): 256-61.
[38]
Yamori Y, Horie R, Handa H, Sato M, Fukase M. Pathogenetic similarity of strokes in stroke-prone spontaneously hypertensive rats and humans. Stroke 1976; 7(1): 46-53.
[39]
Laurent S. Arterial wall hypertrophy and stiffness in essential hypertensive patients. Hypertension 1995; 26(2): 355-62.
[40]
Baumbach GL, Dobrin PB, Hart MN, Heistad DD. Mechanics of cerebral arterioles in hypertensive rats. Circ Res 1988; 62(1): 56-64.
[41]
Baumbach GL, Heistad DD. Cerebral circulation in chronic arterial hypertension. Hypertension 1988; 12(2): 89-95.
[42]
Sorteberg W. Cerebral artery blood velocity and cerebral blood flow. In: Newell DW, Aaslid R, eds Transcranial Doppler. New York, NY: Raven 1992; pp. 57-66.
[43]
Huber P, Handa J. Effect of contrast material, hypercapnia, hyperventilation, hypertonic glucose and papaverine on the diameter of the cerebral arteries. Angiographic determination in man. Invest Radiol 1967; 2(1): 17-32.
[44]
Kalimo H, Fredriksson K, Nordborg C, Auer RN, Olsson Y, Johansson B. The spread of brain oedema in hypertensive brain injury. Med Biol 1986; 64(2-3): 133-7.
[45]
Beausang-Linder M, Bill A. Cerebral circulation in acute arterial hypertension--protective effects of sympathetic nervous activity. Acta Physiol Scand 1981; 111(2): 193-9.
[46]
Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: Associated clinical and radiologic findings. Mayo Clin Proc 2010; 85(5): 427-32.
[47]
Markus HS. Cerebral perfusion and stroke. J Neurol Neurosurg Psychiatry 2004; 75(3): 353-61.
[48]
Atkins ER, Brodie FG, Rafelt SE, Panerai RB, Robinson TG. Dynamic cerebral autoregulation is compromised acutely following mild ischaemic stroke but not transient ischaemic attack. Cerebrovasc Dis 2010; 29(3): 228-35.
[49]
Aries MJ, Elting JW, De Keyser J, Kremer BP, Vroomen PC. Cerebral autoregulation in stroke: A review of transcranial Doppler studies. Stroke 2010; 41(11): 2697-704.
[50]
Strandgaard S, Jones JV, MacKenzie ET, Harper AM. Upper limit of cerebral blood flow autoregulation in experimental renovascular hypertension in the baboon. Circ Res 1975; 37(2): 164-7.
[51]
Jones JV, Fitch W, MacKenzie ET, Strandgaard S, Harper AM. Lower limit of cerebral blood flow autoregulation in experimental renovascular hypertension in the baboon. Circ Res 1976; 39(4): 555-7.
[52]
Castellani S, Bacci M, Ungar A, et al. Abnormal pressure passive dilatation of cerebral arterioles in the elderly with isolated systolic hypertension. Hypertension 2006; 48(6): 1143-50.
[53]
Pantoni L. Cerebral small vessel disease: From pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9(7): 689-701.
[54]
Domanski MJ, Davis BR, Pfeffer MA, Kastantin M, Mitchell GF. Isolated systolic hypertension: Prognostic information provided by pulse pressure. Hypertension 1999; 34(3): 375-80.
[55]
Freitag MH, Peila R, Masaki K, et al. Midlife pulse pressure and incidence of dementia: The Honolulu-Asia Aging Study. Stroke 2006; 37(1): 33-7.
[56]
Qiu C, Winblad B, Viitanen M, Fratiglioni L. Pulse pressure and risk of Alzheimer disease in persons aged 75 years and older: A community-based, longitudinal study. Stroke 2003; 34(3): 594-9.
[57]
Tsivgoulis G, Spengos K, Zakopoulos N, et al. Twenty four hour pulse pressure predicts long term recurrence in acute stroke patients. J Neurol Neurosurg Psychiatry 2005; 76(10): 1360-5.
[58]
Baumbach GL. Effects of increased pulse pressure on cerebral arterioles. Hypertension 1996; 27(2): 159-67.
[59]
Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: A systematic review. Stroke 2003; 34(11): 2741-8.
[60]
Malatino LS, Bellofiore S, Costa MP, Lo Manto G, Finocchiaro F, Di Maria GU. Cerebral blood flow velocity after hyperventilation-induced vasoconstriction in hypertensive patients. Stroke 1992; 23(12): 1728-32.
[61]
Strandgaard S, Olesen J, Skinhoj E, Lassen NA. Autoregulation of brain circulation in severe arterial hypertension. Br Med J 1973; 1(5852): 507-10.
[62]
Strandgaard S. Autoregulation of cerebral blood flow in hypertensive patients. The modifying influence of prolonged antihypertensive treatment on the tolerance to acute, drug-induced hypotension. Circulation 1976; 53(4): 720-7.
[63]
Lábrová R, Honzíková N, Maderová E, et al. Age-dependent relationship between the carotid intima-media thickness, baroreflex sensitivity, and the inter-beat interval in normotensive and hypertensive subjects. Physiol Res 2005; 54(6): 593-600.
[64]
Peckerman A, Hurwitz BE, Nagel JH, Leitten C, Agatston AS, Schneiderman N. Effects of gender and age on the cardiac baroreceptor reflex in hypertension. Clin Exp Hypertens 2001; 23(8): 645-56.
[65]
Robinson TG, Dawson SL, Eames PJ, Panerai RB, Potter JF. Cardiac baroreceptor sensitivity predicts long-term outcome after acute ischemic stroke. Stroke 2003; 34(3): 705-12.
[66]
Liu AJ, Ma XJ, Shen FM, Liu JG, Chen H, Su DF. Arterial baroreflex: a novel target for preventing stroke in rat hypertension. Stroke 2007; 38(6): 1916-23.
[67]
Brunton LL, Chabner BA, Knollmann BC. Goodman & Gilman’s The pharmacological basis of therapeutics. 12th ed. McGraw-Hill Medical: New York 2011; p. 350.
[68]
Bath PM, Krishnan K. Interventions for deliberately altering blood pressure in acute stroke. Cochrane Database Syst Rev 2014; (10): CD000039.
[69]
Qureshi AI. Acute hypertensive response in patients with stroke: Pathophysiology and management. Circulation 2008; 118(2): 176-87.
[70]
Bath P, Chalmers J, Powers W, et al. International Society of Hypertension Writing Group.International Society of Hypertension (ISH): Statement on the management of blood pressure in acute stroke. J Hypertens 2003; 21(4): 665-72.
[71]
Wallace JD, Levy LL. Blood pressure after stroke. JAMA 1981; 246(19): 2177-80.
[72]
Yong M, Diener HC, Kaste M, Mau J. Characteristics of blood pressure profiles as predictors of long-term outcome after acute ischemic stroke. Stroke 2005; 36(12): 2619-25.
[73]
Britton M, Carlsson A, de Faire U. Blood pressure course in patients with acute stroke and matched controls. Stroke 1986; 17(5): 861-4.
[74]
Jauch EC, Saver JL, Adams HP Jr, et al. American Heart Association Stroke Council.Council on Cardiovascular Nursing.; Council on Peripheral Vascular Disease.; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44(3): 870-947.
[75]
Kvistad CE, Logallo N, Oygarden H, Thomassen L, Waje-Andreassen U, Naess H. Elevated admission blood pressure and stroke severity in acute ischemic stroke: The Bergen NORSTROKE Study. Cerebrovasc Dis 2013; 36(5-6): 351-4.
[76]
Hankey GJ. Long-term outcome after ischaemic stroke/transient ischaemic attack. Cerebrovasc Dis 2003; 16(Suppl. 1): 14-9.
[77]
Vemmos KN, Tsivgoulis G, Spengos K, et al. U-shaped relationship between mortality and admission blood pressure in patients with acute stroke. J Intern Med 2004; 255(2): 257-65.
[78]
Ji N, Meng P, Liu N, et al. A reasonable blood pressure level for good clinical outcome after the acute phase of ischemic stroke. J Clin Hypertens (Greenwich) 2016; 18(6): 536-42.
[79]
Rodríguez-García JL, Botia E, de La Sierra A, Villanueva MA, González-Spínola J. Significance of elevated blood pressure and its management on the short-term outcome of patients with acute ischemic stroke. Am J Hypertens 2005; 18(3): 379-84.
[80]
Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA. IST Collaborative Group.Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002; 33(5): 1315-20.
[81]
Okumura K, Ohya Y, Maehara A, Wakugami K, Iseki K, Takishita S. Effects of blood pressure levels on case fatality after acute stroke. J Hypertens 2005; 23(6): 1217-23.
[82]
Berge E, Cohen G, Lindley RI, et al. Effects of blood pressure and blood pressure-lowering treatment during the first 24 hours among patients in the third international stroke trial of thrombolytic treatment for acute ischemic stroke. Stroke 2015; 46(12): 3362-9.
[83]
Ahmed N, Wahlgren N, Brainin M, et al. SITS Investigators. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: Retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke 2009; 40(7): 2442-9.
[84]
ENhanced Control of Hypertension And Thrombolysis strok E StuDy (ENCHANTED). https: //clinicaltrials.gov/ct2/show/NCT01422616?titles=enchanted&rank=1 Accessed June 2017
[85]
Castillo J, Leira R, García MM, Serena J, Blanco M, Dávalos A. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke 2004; 35(2): 520-6.
[86]
Oliveira-Filho J, Silva SC, Trabuco CC, Pedreira BB, Sousa EU, Bacellar A. Detrimental effect of blood pressure reduction in the first 24 hours of acute stroke onset. Neurology 2003 28; 61(8): 1047-51.
[87]
Boreas AM, Lodder J, Kessels F, de Leeuw PW, Troost J. Prognostic value of blood pressure in acute stroke. J Hum Hypertens 2002; 16(2): 111-6.
[88]
Wang H, Tang Y, Rong X, et al. Effects of early blood pressure lowering on early and long-term outcomes after acute stroke: an updated meta-analysis. PLoS One 2014; 9(5): e97917.
[89]
Lee M, Ovbiagele B, Hong KS, et al. Effect of blood pressure lowering in early ischemic stroke: Meta-analysis. Stroke 2015; 46(7): 1883-9.
[90]
Potter JF, Robinson TG, Ford GA, et al. Controlling hypertension and hypotension immediately post-stroke (CHHIPS): A randomised, placebo-controlled, double-blind pilot trial. Lancet Neurol 2009; 8(1): 48-56.
[91]
Hemphill JC III, Greenberg SM, Anderson CS, et al. American Heart Association Stroke Council.Council on Cardiovascular and Stroke Nursing.; Council on Clinical Cardiology. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2015; 46(7): 2032-60.
[92]
Anderson CS, Huang Y, Wang JG, et al. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): A randomized pilot trial. Lancet Neurol 2008; 7(5): 391-9.
[93]
Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013; 368(25): 2355-65.
[94]
Arima H, Anderson CS, Wang JG, et al. Lower treatment blood pressure is associated with greatest reduction in hematoma growth after acute intracerebral hemorrhage. Hypertension 2010; 56(5): 852-8.
[95]
Manning L, Hirakawa Y, Arima H, et al. Blood pressure variability and outcome after acute intracerebral haemorrhage: A post-hoc analysis of INTERACT2, a randomised controlled trial. Lancet Neurol 2014; 13(4): 364-73.
[96]
Wang X, Arima H, Heeley E, et al. Magnitude of blood pressure reduction and clinical outcomes in acute intracerebral hemorrhage: Intensive blood pressure reduction in acute cerebral hemorrhage trial study. Hypertension 2015; 65(5): 1026-32.
[97]
Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med 2016; 375(11): 1033-43.
[98]
Arima H, Chalmers J, Woodward M, et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: The PROGRESS trial. J Hypertens 2006; 24(6): 1201-8.
[99]
Butcher KS, Jeerakathil T, Hill M, et al. The intracerebral hemorrhage acutely decreasing arterial pressure trial. Stroke 2013; 44(3): 620-6.
[100]
Gould B, McCourt R, Gioia LC, et al. Acute blood pressure reduction in patients with intracerebral hemorrhage does not result in borderzone region hypoperfusion. Stroke 2014; 45(10): 2894-9.
[101]
Menon RS, Burgess RE, Wing JJ, et al. Predictors of highly prevalent brain ischemia in intracerebral hemorrhage. Ann Neurol 2012; 71(2): 199-205.
[102]
Garg RK, Liebling SM, Maas MB, Nemeth AJ, Russell EJ, Naidech AM. Blood pressure reduction, decreased diffusion on MRI, and outcomes after intracerebral hemorrhage. Stroke 2012; 43(1): 67-71.
[103]
Gioia L, Klahr A, Kate M, et al. The intracerebral hemorrhage acutely decreasing arterial pressure trial II (ICH ADAPT II) protocol. BMC Neurol 2017; 17(1): 100.
[104]
Yoon SS, Gu Q, Nwankwo T, Wright JD, Hong Y, Burt V. Trends in blood pressure among adults with hypertension: United States, 2003 to 2012. Hypertension 2015; 65(1): 54-61.
[105]
Ford ES, Zhao G, Li C, Pearson WS, Mokdad AH. Trends in obesity and abdominal obesity among hypertensive and non hypertensive adults in the United States. Am J Hypertens 2008; 21(10): 1124-8.
[106]
Meschia JF, Bushnell C, Boden-Albala B, et al. A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45(12): 3754-832.
[107]
Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis. JAMA 2003; 289(19): 2534-44.
[108]
Sipahi I, Swaminathan A, Natesan V, Debanne SM, Simon DI, Fang JC. Effect of antihypertensive therapy on incident stroke in cohorts with prehypertensive blood pressure levels: A meta-analysis of randomized controlled trials. Stroke 2012; 43(2): 432-40.
[109]
Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: A meta-analysis. JAMA 2011; 305(9): 913-22. Erratum in: JAMA 2011; 305(18): 1862.
[110]
Chen N, Zhou M, Yang M, et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev 2010; (8): CD003654.
[111]
Xue H, Lu Z, Tang WL, et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev 2015; 1: CD008170.
[112]
Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350(9080): 757-64.
[113]
SHEP Co-operative Research Group.Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265(24): 3255-64.
[114]
Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358(18): 1887-98.
[115]
Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281-357.
[116]
Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373(22): 2103-16.
[117]
Leenen FH, Dumais J, McInnis NH, et al. Results of the Ontario survey on the prevalence and control of hypertension. CMAJ 2008; 178(11): 1441-9.
[118]
Mancia G, Kjeldsen SE. Adopting systolic pressure intervention trial (SPRINT)-like office blood pressure measurements in clinical practice. J Hypertens 2017; 35(3): 471-2.
[119]
Fodor JG, Baker P, Chen L, Leenen FH. On-treatment blood pressures of older hypertensive patients in Canada: Implications for systolic blood pressure intervention trial. J Hypertens 2017; 35(3): 621-6.
[120]
Qaseem A, Wilt TJ, Rich R, Humphrey LL, Frost J, Forciea MA. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2017; 166(6): 430-7.
[121]
Bress AP, Kramer H, Khatib R, et al. Potential deaths averted and serious adverse events incurred from adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) intensive blood pressure regimen in the United States: Projections from NHANES (National Health and Nutrition Examination Survey). Circulation 2017; 135(17): 1617-28.
[122]
Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: An overview of published reviews. Stroke 2004; 35(4): 1024.
[123]
PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl) 1995; 108(9): 710-7.
[124]
Turnbull F. Blood pressure lowering treatment trialists’ collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 2003; 362(9395): 1527-35.
[125]
Liu L, Wang Z, Gong L, et al. Blood pressure reduction for the secondary prevention of stroke: A Chinese trial and a systematic review of the literature. Hypertens Res 2009; 32(11): 1032-40.
[126]
Ovbiagele B, Diener HC, Yusuf S, et al. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA 2011; 306(19): 2137-44.
[127]
Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: Updated systematic review and meta-analysis. Lancet 2016; 387(10017): 435-43.
[128]
PROGRESS Collaborative Group. Randomised trial of a perindopril- based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358(9287): 1033-41. Erratum in: Lancet 2001; 358(9292): 1556. Lancet 2002; 359(9323): 2120.
[129]
A guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke 2014; 45(7): 2160-236. Erratum in: Stroke. 2015; 46(2): e54. Stroke
[130]
Benavente OR, Coffey CS, Conwit R, et al. Blood-pressure targets in patients with recent lacunar stroke: The SPS3 randomised trial. Lancet. 2013; 382(9891): 507-15. Erratum in: Lancet 2013; 382(9891): 506
[131]
Mant J, McManus RJ, Roalfe A, et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PAST-BP (Prevention After Stroke--Blood Pressure) randomised controlled trial. BMJ 2016; 352: 708.
[132]
Arima H, Chalmers J. PROGRESS: Prevention of recurrent Stroke. J Clin Hypertens (Greenwich) 2011; 13(9): 693-702.
[133]
American Diabetes Association.Standards of medical care in diabetes: 2017. Diabetes Care 2017; 40(Suppl. 1): 75-87.
[134]
Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1575-85.
[135]
Boan AD, Lackland DT, Ovbiagele B. Lowering of blood pressure for recurrent stroke prevention. Stroke 2014; 45(8): 2506-13.
[136]
De Lima LG, Saconato H, Atallah AN, da Silva EM. Beta-blockers for preventing stroke recurrence. Cochrane Database Syst Rev 2013; 10: CD007890.
[137]
Barer DH, Cruickshank JM, Ebrahim SB, Mitchell JR. Low dose beta blockade in acute stroke (“BEST” trial): An evaluation. Br Med J (Clin Res Ed) 1988; 296(6624): 737-41.
[138]
Webb AJ, Rothwell PM. Effect of dose and combination of antihypertensives on interindividual blood pressure variability: A systematic review. Stroke 2011; 42(10): 2860-5.
[139]
Schrader J, Lüders S, Kulschewski A, et al. MOSES Study Group.Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36(6): 1218-26.
[140]
Villapol S, Saavedra JM. Neuroprotective effects of angiotensin receptor blockers. Am J Hypertens 2015; 28(3): 289-99.
[141]
Rothwell PM, Howard SC, Spence JD. Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease. Stroke 2003; 34(11): 2583-90.
[142]
Powers WJ. Cerebral hemodynamics in ischemic cerebrovascular disease. Ann Neurol 1991; 29(3): 231-40.
[143]
Giannopoulos A, Kakkos S, Abbott A, et al. Long-term mortality in patients with asymptomatic carotid stenosis: Implications for statin therapy. Eur J Vasc Endovasc Surg 2015; 50(5): 573-82.
[144]
Phillips RA. Hypertension treatment and outcomes in the era of population health, coordinated care, and Medicare Access and CHIP Reauthorization Act (MACRA). Circulation 2017; 135(17): 1629-31.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 1
Year: 2019
Page: [72 - 84]
Pages: 13
DOI: 10.2174/1570161115666171116151051
Price: $58

Article Metrics

PDF: 31
HTML: 3